Evidence map›Paper›PMID 36149458›Full record

ReviewDer Nervenarzt2023

[Nuclear medicine diagnostics in Wilson's disease].

W Hermann, S Hesse

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

W HermannAbteilung Neurologie, SRO Langenthal, St. Urbanstr. 67, 4900, Langenthal, Schweiz. w.hermann@sro.ch.
S HesseKlinik und Poliklinik für Nuklearmedizin, Universität Leipzig, Leipzig, Deutschland.
Klinik und Poliklinik für Nuklearmedizin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wilson's disease is an autosomal recessive disorder of copper metabolism and is caused by a genetic defect on chromosome 13. Nuclear medicine methods can prove the metabolic defect and contribute to the assessment of central neurological deficits.With high specificity and sensitivity, the intravenous radiocopper test enables the diagnosis to be confirmed as the basis for initiating treatment. The oral radiocopper test is used to monitor zinc treatment.[

Indexed as

Hepatolenticular DegenerationNuclear MedicineCocaineFluorodeoxyglucose F18HumansIodine Radioisotopes2beta-carbomethoxy-3beta-(4-iodophenyl)tropaneCocaineFluorodeoxyglucose F18Iodine-123Iodine Radioisotopes[123I]IBZM-SPECT[123I]β-CIT-SPECT[18F]FDG-PETRadiocopper testSerotonin transporter

Identifiers

PMID36149458
OpenAlexW4296794496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.